Helsinn Healthcare SA has returned elsiglutide, a treatment for chemotherapy-induced diarrhoea, to its creator, Zealand Pharma A/S, thus ending a partnership agreement to develop the drug further. ---Subscribe to MedNous to access this article--- Company News
